Experimental autoimmune encephalomyelitis: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{DISPLAYTITLE:Experimental Autoimmune Encephalomyelitis}} | |||
{{ | {{Infobox medical condition | ||
| name = Experimental Autoimmune Encephalomyelitis | |||
| image = | |||
| caption = | |||
| field = Neurology, Immunology | |||
| symptoms = Paralysis, weight loss, inflammation of the central nervous system | |||
| complications = Chronic neurological deficits | |||
| onset = Induced in laboratory settings | |||
| duration = Variable, depending on the model | |||
| causes = Autoimmune response against myelin | |||
| risks = Genetic predisposition, environmental factors | |||
| diagnosis = Clinical observation in animal models | |||
| treatment = Immunomodulatory therapies in research | |||
}} | |||
'''Experimental Autoimmune Encephalomyelitis''' ('''EAE''') is an [[animal model]] of the human [[disease]] [[multiple sclerosis]] (MS). It is used extensively in [[research]] to study the [[pathogenesis]] of [[autoimmune]] diseases and to test potential [[therapies]]. | |||
==Pathophysiology== | |||
EAE is characterized by an [[autoimmune]] response against the [[myelin]] sheath of the [[central nervous system]] (CNS). This response is mediated by [[T cells]], particularly [[CD4+ T helper cells]], which recognize [[myelin]] antigens as foreign. The activation of these [[T cells]] leads to the recruitment of other [[immune cells]], such as [[macrophages]] and [[B cells]], resulting in [[inflammation]] and [[demyelination]] of [[neurons]]. | |||
===Induction=== | |||
EAE can be induced in various [[animal models]], including [[mice]], [[rats]], and [[non-human primates]]. The induction is typically achieved by [[immunization]] with [[myelin]] proteins or peptides, such as [[myelin oligodendrocyte glycoprotein]] (MOG), [[myelin basic protein]] (MBP), or [[proteolipid protein]] (PLP), emulsified in [[adjuvants]] like [[complete Freund's adjuvant]] (CFA). Alternatively, EAE can be induced by the passive transfer of [[activated T cells]] specific for [[myelin]] antigens. | |||
==Clinical Features== | |||
The clinical presentation of EAE varies depending on the [[species]] and [[strain]] of the [[animal model]] used. Common symptoms include [[paralysis]], [[weight loss]], and [[inflammation]] of the [[CNS]]. The disease course can be monophasic, relapsing-remitting, or chronic-progressive, mimicking different forms of [[multiple sclerosis]]. | |||
==Histopathology== | |||
Histological examination of the [[CNS]] in EAE reveals [[perivascular]] [[infiltrates]] of [[lymphocytes]] and [[macrophages]], [[demyelination]], and [[axonal damage]]. These pathological features are similar to those observed in [[multiple sclerosis]] lesions. | |||
==Research Applications== | |||
EAE is a valuable tool for studying the [[immunological]] mechanisms underlying [[autoimmune]] diseases. It has been instrumental in identifying key [[cytokines]], such as [[interferon-gamma]] and [[interleukin-17]], that drive the [[inflammatory]] process. EAE is also used to evaluate the efficacy of potential [[therapeutic]] agents, including [[immunomodulatory drugs]], [[monoclonal antibodies]], and [[vaccines]]. | |||
==Limitations== | |||
While EAE provides important insights into the [[pathogenesis]] of [[multiple sclerosis]], it is not a perfect model. Differences in [[genetics]], [[immune system]] function, and [[CNS]] structure between [[humans]] and [[animals]] can limit the direct translation of findings. Additionally, EAE is an induced condition, whereas [[multiple sclerosis]] arises spontaneously in [[humans]]. | |||
==Conclusion== | |||
Experimental Autoimmune Encephalomyelitis remains a cornerstone in [[neuroimmunology]] research. Despite its limitations, it continues to provide valuable information on the [[immune]] mechanisms involved in [[CNS]] [[autoimmunity]] and serves as a platform for testing new [[therapeutic]] strategies. | |||
{{Medical resources}} | |||
[[Category:Autoimmune diseases]] | |||
[[Category:Neurology]] | |||
[[Category:Immunology]] | |||
[[Category:Animal models of disease]] | |||
Latest revision as of 21:35, 1 January 2025
| Experimental Autoimmune Encephalomyelitis | |
|---|---|
| Synonyms | N/A |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Paralysis, weight loss, inflammation of the central nervous system |
| Complications | Chronic neurological deficits |
| Onset | Induced in laboratory settings |
| Duration | Variable, depending on the model |
| Types | N/A |
| Causes | Autoimmune response against myelin |
| Risks | Genetic predisposition, environmental factors |
| Diagnosis | Clinical observation in animal models |
| Differential diagnosis | N/A |
| Prevention | N/A |
| Treatment | Immunomodulatory therapies in research |
| Medication | N/A |
| Prognosis | N/A |
| Frequency | N/A |
| Deaths | N/A |
Experimental Autoimmune Encephalomyelitis (EAE) is an animal model of the human disease multiple sclerosis (MS). It is used extensively in research to study the pathogenesis of autoimmune diseases and to test potential therapies.
Pathophysiology[edit]
EAE is characterized by an autoimmune response against the myelin sheath of the central nervous system (CNS). This response is mediated by T cells, particularly CD4+ T helper cells, which recognize myelin antigens as foreign. The activation of these T cells leads to the recruitment of other immune cells, such as macrophages and B cells, resulting in inflammation and demyelination of neurons.
Induction[edit]
EAE can be induced in various animal models, including mice, rats, and non-human primates. The induction is typically achieved by immunization with myelin proteins or peptides, such as myelin oligodendrocyte glycoprotein (MOG), myelin basic protein (MBP), or proteolipid protein (PLP), emulsified in adjuvants like complete Freund's adjuvant (CFA). Alternatively, EAE can be induced by the passive transfer of activated T cells specific for myelin antigens.
Clinical Features[edit]
The clinical presentation of EAE varies depending on the species and strain of the animal model used. Common symptoms include paralysis, weight loss, and inflammation of the CNS. The disease course can be monophasic, relapsing-remitting, or chronic-progressive, mimicking different forms of multiple sclerosis.
Histopathology[edit]
Histological examination of the CNS in EAE reveals perivascular infiltrates of lymphocytes and macrophages, demyelination, and axonal damage. These pathological features are similar to those observed in multiple sclerosis lesions.
Research Applications[edit]
EAE is a valuable tool for studying the immunological mechanisms underlying autoimmune diseases. It has been instrumental in identifying key cytokines, such as interferon-gamma and interleukin-17, that drive the inflammatory process. EAE is also used to evaluate the efficacy of potential therapeutic agents, including immunomodulatory drugs, monoclonal antibodies, and vaccines.
Limitations[edit]
While EAE provides important insights into the pathogenesis of multiple sclerosis, it is not a perfect model. Differences in genetics, immune system function, and CNS structure between humans and animals can limit the direct translation of findings. Additionally, EAE is an induced condition, whereas multiple sclerosis arises spontaneously in humans.
Conclusion[edit]
Experimental Autoimmune Encephalomyelitis remains a cornerstone in neuroimmunology research. Despite its limitations, it continues to provide valuable information on the immune mechanisms involved in CNS autoimmunity and serves as a platform for testing new therapeutic strategies.